Диссертация (1154919), страница 18
Текст из файла (страница 18)
128. — P. 343-350.108. Ceni E. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism /Ceni E., Mello T., Galli A. // World J Gastroenterol 2014 December 21; 20(47): 1775617772109. Chang T.T. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosisand continued histological improvement in patients with chronic hepatitis B / ChangT.T., Liaw Y.F., Wu S.S., Schiff E., Han K.H., Lai C.L., Safadi R., Lee S.S., Halota W.,Goodman Z., Chi Y.C., Zhang H., Hindes R., Iloeje U., Beebe S., Kreter B. //Hepatology.
2010 Sep;52(3):886-93.110. Chen–Hua Liu, Shih–Jer Hsu, Jou–Wei Lin et al. Noninvasive Diagnosis ofHepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler ImpedanceIndex // J Clin Gatstroener, 2007, 5:1199-1206.111. Corpechot C. Assessment of biliary fibrosis by transient elastography in patientswith PBC and PSC / Corpechot C., El Naggar A., Poujol-Robert A., et al.
// Hepatology2006;43:1118-1124112. Corpechot, C., El Naggar, A., Poupon, R. Gender and liver: is the liver stiffnessweaker in weaker sex? // Hepatology. 2006;44:513–514.113. Curgunlu A., Vural P., Canbaz M., Erten N., Karan M.A., Tascioglu C. Plasmanitrate/nitrite and endothelin-1 in patients with liver cirrhosis // J. Clin. Lab. Anal. 2005;19:177-181.114. D’Ambrosio R. The diagnostic accuracy of Fibroscan for cirrhosis is influenced byliver morphometry in HCV patients with a sustained virological response / D’AmbrosioR., Aghemo A., Fraquelli M., Rumi M.G., Donato M.F., Paradis V., et al.
// J Hepatol2013;59:251–6.99115. Deuffic-Burban S, Babany G, Lonjon-Domanec I, et al. Impact of pegylatedinterferon and ribavirin on morbidity and mortality in patients with chronic hepatitis Cand normal aminotransferases in France. Hepatology. 2009;50:1351–59.116. Diehl A. Liver disease in alcohol abusers: clinical perspective / Diebl A. // Alcohol2002; 27: 7–11.117. Dietrich C.F. Current status and perspectives of elastography / Dietrich C.F.,Cantisani V. // Eur J Radiol 2014; 83: 403-404118.
DiNicolantonio J.J. Should torsemide be the loop diuretic of choice in systolicheart failure? Future Cardiol 2012;8:707—728.119. EASL (European Association for the Study of the Liver) clinical practiceguidelines on the management of ascites, spontaneous bacterial peritonitis, andhepatorenal syndrome in cirrhosis. August 2010.120. EASL clinical practical guidelines: management of alcoholic liver disease // JHepatol. 2012 Aug;57(2):399-420.121. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation ofliver disease severity and prognosis. Journal of Hepatology 2015; 63:237-264.122. EASL Clinical Practice Guidelines: management of hepatitis C virus infection // JHepatol 2011;55:245–264.123.
Felker G. M., Diuretic Management in Heart Failure. Congest Heart Fail.2010;16(4)(suppl 1):68–72.124. Ferard C. Intermethod calibration of alanine aminotransferase (ALT) andgammaglutamyltransferase (GGT) results: application to FibroTest and ActiTest scores /Ferard C., Piton A., Messous D. et al.
// Clin. Chem. Lab. Med. — 2006. — 44. — 400406.100125. Fiaccadori F. Torasemide versus furosemide in cirrhosis: a long-term, double-blind,randomized clinical study / Fiaccadori F., Pedretti G., Pasetti G., Pizzaferri P., Elia G. //Clin Invest 1993;71:7:579–584.126. Fisher N.C., Neil D.A.H., Williams A., Adams D.H. Serum concentrations andperipheral secretion of the beta-chemokines monocyte chemoattractant protein 1 andmacrophage inflammatory protein 1α in alcoholic liver disease // Gut. 1999; 45: 16-420.127. Fisher N., Afford S., Adams D.H.
Adhesion molecules and alcoholic liver disease //Hepato-Gastroenterol. 1996; 43:1113-1116.128. Flisiak R. Plasma tissue inhibitor of metalloproteinases-1 and transforming growthfactor beta 1-possible non-invasive biomarkers of hepatic fibrosis in patients withchronic B and C hepatitis.
/ Flisiak R., Maxwell P., Prokopowicz D., Timms P.M.,Panasiuk A. // Hepatogastroenterology. – 2002. – v. 49. – p. 1369–1372.129. Foucher J., Chanteloup E., Vergniol J. et all., Diagnosis of cirrhosis by transientelastography (FibroScan): a prospective study // Gut 2006;55:403–408.130. Foucher J. Prevalence and factors associated with failure of liver stiffnessmeasurement using FibroScan in a prospective study of 2114 examinations / Foucher J.,Castera L., Bernard P.H., et al. // Eur J Gastroenterol Hepatol 2006;18:411–412.131. Francoise D. Practices of Liver Biopsy in France: Results of ProspectiveNationwide Survey / Francoise D.
// J Hepatol 2011; 32 (6): 1403—1408.132. Fraquelli M. Reproducibility of transient elastography in the evaluation of liverfibrosis in patients with chronic liver disease / Fraquelli M., Rigamonti C., Casazza G.,Conte D., Donato M.F., Ronchi G., Colombo M. // Gut 2007; 56: 968-973.133.
Friedman S. Mechanisms of disease: mechanisms of hepatic fibrosis andtherapeutic implications // Nat. Clin. Prac. Gastroenterol. Hepatol. 2004; 1: 98–105.101134. Friedrich-Rust M., Ong M.F., Martens S., et al. Performance of transientelastography for the staging of liver fibrosis: A meta-analysis // Gastroenterology2008;134:960-974.135. Ganne-Carrie N. Accuracy of liver stiffness measurement for the diagnosis ofcirrhosis in patients with chronic liver diseases / Ganne-Carrie N., Ziol M., deLedinghen V., Douvin C., Marcellin P., Castera L, et al. // Hepatology 2006;44:1511–1517.136.
Gennisson J.L. Ultrasound elastography: principles and techniques / GennissonJ.L., Deffieux T., Fink M., Tanter M. // Diagn Interv Imaging 2013; 94: 487-495.137. Gerbes A., Bertheau-Reitha U., Falkner C., Junqst D., Paumqartner G. Advantagesof the new loop diuretic torasemide over furosemide in patients with cirrhosis andascites. A randomized, double blind cross-over trial // J Hepatol 1993;17:3:353–358.138. Ghany M. Assessment of liver fibrosis: palpate, poke or pulse? / Ghany M., Doo E.// Hepatology.— 2005. — Vol. 42, № 4. — P. 759–761.139. Global status report on alcohol and health.
2014.140. Gonçalves A. Alcohol consumption and risk of heart failure: the AtherosclerosisRisk in Communities Study / Gonçalves A., Claggett B., Jhund P., Rosamond W.,Deswal A., Aguilar D., Shah A., Cheng S., Solomon S. // European Heart Journal,jan.2015.141. Gropper S., Albet C., Guglietta A. Gich I, Barbanoj M.J. Single–dose, randomized,cross–over, bioavailability pilot clinical trial of torasemide immediate release comparedto a new prolonged release formulation of torasemide [abstract], Basic Clin. Pharmacol.Toxicol 2006;Vol. 99 (Suppl. 1), 48.142. Hepatology: Textbook and Atlas. 3d edition. E.
Kuntz, H.-D.Kuntz, SpringerScience & Business Media, 2009 г., с. 937; liver biopsy.102143. Hui C.-P. A comparison in the progression of liver fibrosis in chronic hepatitisbetween persistanly normal and elevated transaminase / Hui C.-P., Belaye T.,Montegrand K., Wright T.L. // J. Hepatol. 2003. V. 38. P.
511-517.144. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview // CurrentMolecular Medicine 2003; 3: 483–90.145. Hirayama C. Serum type IV collagen in various liver diseases in comparison withserum 7S collagen, laminin, and type III procollagen peptide / Hirayama C., Suzuki H.,Takada A., Fujisawa K., Tanikawa K., Igarashi S. // J. Gastroenterol. 1996; 31: 242-248.146.
Huang Z., Chen X., Zhao Q., Zheng Y., Peng L., Gao Z. et al. An albumin, collagenIV, and longitudinal diameter of spleen scoring system superior to APRI for assessingliver fibrosis in chronic hepatitis B patients // Int. J. Infec. Dis. 2015; 31: 18-22.147. Huang YS., Wu JC., Chang FY., Lee SD. Interleukin-8 and alcoholic liver disease.Zhonghua Yi Xue Za Zhi (Taipei).
1999 Jul;62(7):395-401.148. International Ascites Club, ICA, 1996.149. Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portalhypertension // Liver Int. 2012; 32: 199-213.150. Jung M.K. Comparison of transient elastography and hepatic fibrosis assessed byhistology in chronic liver disease / Jung M.K., Cho H.J., Lee H.C., Park K.S., Seo E.H.,Jeon S.W., Cho C.M., Tak W.Y., Kim S.K., Choi Y.H., Kweon Y.O. // Korean JGastroenterol.
2008 Apr;51(4):241-247.151. JohansenJS Serum YKL-40 is increased in patients with hepatic fibrosis /Johansen JS, Christoffersen P, Møller S, Price PA, Henriksen JH, Garbarsch C. //J Hepatol 2000;32:911 – 920.152. Kanda H MCP-1 contributes to macrophage infiltration into adipose tissue, insulinresistance, and hepatic steatosis in obesity / Kanda H, Tateya S, Tamori Y, Kotani K,103Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M // J ClinInvest. 2006 Jun; 116(6):1494-505.153. Kanzler S. Prediction of progressive liver fibrosis in hepatitis C infection by serumand tissue levels of transforming growth factor-beta. / Kanzler S., Baumann M.,Schirmacher P., et al.
// J. Viral Hepat. – 2001. – v. 8. – p. 430–437.154. Kawaratani H., Tsujimoto T., Douhara A., Takaya H., Moriya K., Namisaki T., etal. The effect of inflammatory cytokines in alcoholic liver disease // Mediators ofinflammation. 2013; 2013: 1-10.155. Kim S.U. What are 'true normal' liver stiffness values using FibroScan?: aprospective study in healthy living liver and kidney donors in South Korea / Kim S.U.,Choi G.H., Han W.K., Kim B.K., Park J.Y., Kim D.Y., Choi J.S., Yang S.C., Choi E.H.,Ahn S.H., Han K.H., Chon C.Y.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
